ERBB2 and non-small cell lung carcinoma: Recently, HER2 mutations have been identified as potential therapeutic targets, with fam-trastuzumab-deruxtecan exhibiting promising efficacy and receiving the approval of the U.S. Food and Drug Administration for both HER2-mutant and HER2-amplified NSCLC.